Technology Bundle ID
TAB-2672

Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel

Linked ID
E-331-2013-0
Lead Inventors
Stephen Lindstrom (CDC)
Co-Inventors
Alexander Klimov (CDC)
Lamorris Loftin (CDC)
Nancy Cox (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
ICs
CDC
This invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. Unlike culture and serological tests requiring 5 to 14 days for completion, CDC researchers developed a rapid, accurate assay, which is easily adapted to kit form. This assay also requires less labor input than immunoassays. These methods can be used to quickly identify a broad variety of influenza types and subtypes, including viruses that may be involved in pandemics (such as H5N1, for example).
Commercial Applications
  • Influenza diagnostic using clinical specimens
  • High-throughput screenings
  • Influenza surveillance programs
Competitive Advantages
  • Already FDA approved
  • Especially useful for H5N1 screening
  • Sensitive detection
  • Specific discrimination of influenza subtypes
  • Easily formatted as kit or array
  • Faster than culturing and serological identification methods
  • Less laborious and more objective than immunoassays

Request More Info

Licensing Contact: